烟台市新生儿乙肝疫苗策略卫生经济学评价  

Impact and Health Economic of Hepatitis B Vaccination for the Infant Population in Yantai

作　　者：李波[1] 崔伟红[1] 衣学梅[1] 李娜[1] 石义全[1] 

机构地区：[1]山东省烟台市疾病预防控制中心,山东烟台264003

出　　处：《中国卫生经济》2013年第3期81-83,共3页Chinese Health Economics

摘　　要：目的:完善烟台市乙肝免疫预防策略以及中长期防治规划提供依据。方法:分析烟台市1992—2011年新生儿乙肝疫苗接种产生的经济效益和社会效益,进行卫生经济学评价。结果:新生儿乙肝免疫接种投入成本0.37亿(2011年贴现值),产出效益27.62亿,净效益(NB)为27.25亿,效益成本比(BCR)为75.04;估计挽回乙肝、肝硬化、肝癌的疾病总负担为43 472个DALY,挽回1个DALY的成本为846.72元。20年接种预计将减少HBsAg阳性携带者76 710人,减少慢性乙肝患者7 671人,减少肝硬化患者767人,减少肝癌患者77人。结论:实施20年新生儿乙肝疫苗免疫获得巨大经济效益和社会效益。现行的新生儿优先接种并保持高覆盖率的策略仍为合理方案。Objective： To learn the effect and economic benefit of hepatitis B （HB） vaccination and provide basis for middle long prevention plan for HB. Methods： The cost and benefit study of HB from 1992 to 2011 were analyzed. Results： Cost benefit study showed that discounted cost was 37 million RMB; production benefit was 2.76 billion RMB and net benefit was 2.73 billion RMB. Ratio of cost and benefit was 75.04 and a 4 3472 DALY was reduced. Social benefit analysis showed that 7 6710 HBsAg positive people,7671 chronic HB patients, 767 cirrhosis patients,77 liver cancer patients were prevented from 1992 to 2011. Conclusion： The strategy of hepatitis B vaccination performed among the infants in Yantai for 20 year obtained significant economic and social benefit. In the following years, the immunization of newborns was still the preferential strategy from a societal perspective.

关 键 词：乙肝疫苗 预防接种 卫生经济学 评价 

分 类 号：R186[医药卫生—流行病学]